国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2015年
4期
605-607
,共3页
黄文志%李倩庆%王露%张伟
黃文誌%李倩慶%王露%張偉
황문지%리천경%왕로%장위
氧诱导视网膜新生血管性病变%视网膜新生血管%促红细胞生成素
氧誘導視網膜新生血管性病變%視網膜新生血管%促紅細胞生成素
양유도시망막신생혈관성병변%시망막신생혈관%촉홍세포생성소
oxygen - induced retinopathy%retinal neovascularization%erythropoietin
目的：建立C57 BL/6小鼠氧致血管增生性视网膜病变模型( oxygen induced retinopathy, OIR),探讨阻断促红细胞生成素( Erythropoietin, EPO )对视网膜新生血管的抑制作用。<br> 方法：取鼠龄7 d ( P7)的健康C57 BL/6小鼠置于75%±2%氧气浓度的密闭氧舱中5d,鼠龄12d (P12)时返回正常空气环境以建立氧诱导鼠视网膜新生血管模型；新生小鼠于P12~P16隔日给予玻璃体腔内注射0.5μL含有25ng(A组),50ng(B组),250ng(C组)可溶性EPO受体的PBS液以及不含EPO受体的PBS液( D组)。于P17时分批处死各组小鼠,小鼠眼球以4%多聚甲醛固定,制成病理切片,进行视网膜组织形态病理学观察计数突破内界膜新生血管细胞核数,了解视网膜新生血管增生程度。<br> 结果：计数病理切片突破内界膜新生血管细胞核数目,各组玻璃体内EPO受体注射组较PBS注射组新生血管细胞核数明显减少,差异有统计学意义(P<0.01)。并且各不同浓度EPO受体组间新生血管细胞核计数差异亦有统计学意义(P<0.01),随着EPO受体浓度增高,突破内界膜新生血管内皮细胞数减少。<br> 结论：可溶性EPO受体玻璃体腔内注射能够阻断EPO的促新生血管生成作用,有望成为治疗眼部新生血管性疾病的新方法。
目的：建立C57 BL/6小鼠氧緻血管增生性視網膜病變模型( oxygen induced retinopathy, OIR),探討阻斷促紅細胞生成素( Erythropoietin, EPO )對視網膜新生血管的抑製作用。<br> 方法：取鼠齡7 d ( P7)的健康C57 BL/6小鼠置于75%±2%氧氣濃度的密閉氧艙中5d,鼠齡12d (P12)時返迴正常空氣環境以建立氧誘導鼠視網膜新生血管模型；新生小鼠于P12~P16隔日給予玻璃體腔內註射0.5μL含有25ng(A組),50ng(B組),250ng(C組)可溶性EPO受體的PBS液以及不含EPO受體的PBS液( D組)。于P17時分批處死各組小鼠,小鼠眼毬以4%多聚甲醛固定,製成病理切片,進行視網膜組織形態病理學觀察計數突破內界膜新生血管細胞覈數,瞭解視網膜新生血管增生程度。<br> 結果：計數病理切片突破內界膜新生血管細胞覈數目,各組玻璃體內EPO受體註射組較PBS註射組新生血管細胞覈數明顯減少,差異有統計學意義(P<0.01)。併且各不同濃度EPO受體組間新生血管細胞覈計數差異亦有統計學意義(P<0.01),隨著EPO受體濃度增高,突破內界膜新生血管內皮細胞數減少。<br> 結論：可溶性EPO受體玻璃體腔內註射能夠阻斷EPO的促新生血管生成作用,有望成為治療眼部新生血管性疾病的新方法。
목적：건립C57 BL/6소서양치혈관증생성시망막병변모형( oxygen induced retinopathy, OIR),탐토조단촉홍세포생성소( Erythropoietin, EPO )대시망막신생혈관적억제작용。<br> 방법：취서령7 d ( P7)적건강C57 BL/6소서치우75%±2%양기농도적밀폐양창중5d,서령12d (P12)시반회정상공기배경이건립양유도서시망막신생혈관모형；신생소서우P12~P16격일급여파리체강내주사0.5μL함유25ng(A조),50ng(B조),250ng(C조)가용성EPO수체적PBS액이급불함EPO수체적PBS액( D조)。우P17시분비처사각조소서,소서안구이4%다취갑철고정,제성병리절편,진행시망막조직형태병이학관찰계수돌파내계막신생혈관세포핵수,료해시망막신생혈관증생정도。<br> 결과：계수병리절편돌파내계막신생혈관세포핵수목,각조파리체내EPO수체주사조교PBS주사조신생혈관세포핵수명현감소,차이유통계학의의(P<0.01)。병차각불동농도EPO수체조간신생혈관세포핵계수차이역유통계학의의(P<0.01),수착EPO수체농도증고,돌파내계막신생혈관내피세포수감소。<br> 결론：가용성EPO수체파리체강내주사능구조단EPO적촉신생혈관생성작용,유망성위치료안부신생혈관성질병적신방법。
AIM:To establish the murine model of oxygen induced retinopathy ( OIR) and to evaluate the inhibition of retinal neovascularization by erythropoietin ( EPO) blockade. <br> METHODS: Neonates of C57BL/6 mouse ( P7 ) were exposed to 75%±2% oxygen for 5d and return to normal air environment when 12d ( P12 ) to establish oxygen-induced retinal neovascularization model. The neonates were divided into groups, injected with 0. 5μL solution containing 25ng ( group A), 50ng ( group B), 250ng ( group C) of soluble erythropoietin receptor ( EPO-R) or PBS (group D) at P12, P14 and P16 in the right eye. On P17, the litters were sacrificed and their right eyes were enucleated and fixed with 4% paraformaldehyde, made pathological section. The number of breakthrough internal limiting membrane neovascular nuclei was counted with pathological retinal morphology, understanding theproliferative degree of retinal neovascularization. <br> RESULTS: The pathological sections showed the neovascular cell nuclei which penetrating the inner limiting membrane in intravitreal EPO receptor injection group was reduced statistically than that in PBS injection group, the difference was statistically significant ( P<0.01). And, neovascular nuclei count differences in the <br> various concentrations of EPO receptor group was statistically significant (P<0. 01). With the EPO receptor concentration increase, neovascular endothelial cells broken through the internal limiting membrane was reduced. <br> CONCLUSION: Intravitreal injection of soluble EPO receptor can block EPO and improve neovascularization. The new method is expected to become new treatment of ocular neovascular diseases.
